[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100600167":3},{"organization":4,"outcomesModule":7,"designInfo":63,"detailedDescription":69,"studyPopulation":62,"armGroups":70,"interventions":77,"overallOfficials":82,"centralContacts":90,"locations":96,"responsibleParty":131,"collaborators":62,"id":133,"slug":62,"hasResults":134,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":62,"eligibilityCriteria":138,"healthyVolunteers":134,"sex":139,"minAge":140,"maxAge":141,"enrollmentInfo":142,"targetDuration":62,"studyType":145,"phases":146,"briefSummary":149,"conditions":150,"keywords":152,"overallStatus":99,"whyStopped":62,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":163},{"fullName":5,"class":6},"Lepu Biopharma Co., Ltd.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":27,"otherOutcomes":62},[9,13,17,21,24],{"measure":10,"description":11,"timeFrame":12},"Maximum Tolerated Dose (MTD) - Phase I","The highest dose confirmed wherein less than 2 out of 6, or \\\u003C 33% of evaluable patients in a treatment cohort experiences dose-limiting toxicity (DLT).","Baseline to the end of the first treatment cycle (each cycle is 21 days).",{"measure":14,"description":15,"timeFrame":16},"Recommended Phase II Dose (RP2D) - Phase I","The dose level of MRG006A recommended for further clinical studies based on assessment of the safety, efficacy and PK data from this study.","Baseline to study completion (up to 24 months).",{"measure":18,"description":19,"timeFrame":20},"Adverse Events (AEs) - Phase I","Any reaction, side effect, or untoward event that occurs during the course of the clinical trial whether or not the event is considered related to the study drug.","Baseline to 30 days after the last dose of study treatment.",{"measure":22,"description":23,"timeFrame":20},"Serious Adverse Events (SAEs) - Phase I","Adverse events that are fatal, life-threatening, or result in hospitalization or prolonged hospitalization, persistent or significant disability\u002Fincapacity\u002Fsubstantial disruption of the ability to lead a normal life, congenital anomaly\u002Fbirth defect or major medical events or reactions.",{"measure":25,"description":26,"timeFrame":16},"Objective Response Rate (ORR)- Phase II","ORR is defined as the proportion of subjects with CR and PR assessed by IRC and investigator according to RECIST v1.1 and mRECIST（HCC patients）. And determine the objective response rate (CR + PR) and its 95% confidence interval.",[28,30,33,36,39,42,45,48,51,54,58,60],{"measure":29,"description":26,"timeFrame":16},"Objective Response Rate (ORR) - Phase I",{"measure":31,"description":32,"timeFrame":16},"Overall Survive (OS)- Phase II","The time from start of study treatment to date of death as a result of any cause.",{"measure":34,"description":35,"timeFrame":16},"Duration of Response (DoR)","The time interval between the date of the earliest qualifying response and the date of disease progression or death for any cause, whichever occurs earlier.",{"measure":37,"description":38,"timeFrame":16},"Disease Control Rate (DCR)","The proportion of patients who achieve CR, PR, or stable disease (SD) after treatment.",{"measure":40,"description":41,"timeFrame":16},"Progression Free Survival (PFS)","The time from the date of first study dose to disease progression or death whichever occurs first.",{"measure":43,"description":44,"timeFrame":20},"Cmax","Maximum observed blood concentration",{"measure":46,"description":47,"timeFrame":20},"Tmax","Time to reach the maximum blood concentration.",{"measure":49,"description":50,"timeFrame":20},"AUC0-t","Area under the blood concentration-time curve from time 0 to the time of last quantifiable concentration.",{"measure":52,"description":53,"timeFrame":20},"Incidence of anti-drug antibody (ADA)","The proportion of patients with positive ADA results.",{"measure":55,"description":56,"timeFrame":57},"QT interval corrected by Fridericia's formula（QTcF）","Evaluate the effect of MRG006A on the prolongation of QT interval corrected by heart rate using Fridericia's formula (QTcF) in patients with advanced solid tumors.","Baseline to 15 days after the third dose of study treatment.",{"measure":59,"description":19,"timeFrame":20},"Adverse Events (AEs) - Phase II",{"measure":61,"description":23,"timeFrame":20},"Serious Adverse Events (SAEs) - Phase II",null,{"allocation":64,"interventionModel":65,"interventionModelDescription":62,"primaryPurpose":66,"observationalModel":62,"timePerspective":62,"maskingInfo":67},"NA","SINGLE_GROUP","TREATMENT",{"masking":68,"maskingDescription":62,"whoMasked":62},"NONE","This study consists of two parts. Phase I is a dose escalation study to determine the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of MRG006A. Phase II is a dose expansion study to further assess the efficacy, safety, pharmacokinetics and immunogenicityof MRG006A at confirmed RP2D.",[71],{"label":72,"type":73,"description":74,"interventionNames":75},"MRG006A","EXPERIMENTAL","All patients in Phase I and Phase II will be administrated MRG006A on Day 1 of every 3 weeks (21-day cycle).",[76],"Drug: MRG006A",[78],{"type":79,"name":72,"description":80,"armGroupLabels":81,"otherNames":62},"DRUG","Administrated intravenously",[72],[83,87],{"name":84,"affiliation":85,"role":86},"Jian Zhou, M.D.","Fudan University","PRINCIPAL_INVESTIGATOR",{"name":88,"affiliation":89,"role":86},"Hong Zhao, M.D.","Cancer Institute and Hospital, Chinese Academy of Medical Sciences",[91],{"name":92,"role":93,"phone":94,"phoneExt":62,"email":95},"Program Director","CONTACT","86-21-61637960","clinicaltrials@miracogen.com.cn",[97,116],{"facility":98,"status":99,"city":100,"state":101,"zip":102,"country":103,"countryCode":104,"cosmosGeoPoint":105,"geoPoint":110,"contacts":111},"Cancer Hospital Chinese Academy of Medical Sciences","RECRUITING","Beijing","Beijing Municipality","100021","China","CN",{"type":106,"coordinates":107},"Point",[108,109],116.39723,39.9075,{"lat":109,"lon":108},[112],{"name":113,"role":93,"phone":114,"phoneExt":62,"email":115},"Hong Zhao, M.D","86-10-87787100","zhou.jian@zs-hospital.sh.cn",{"facility":117,"status":99,"city":118,"state":119,"zip":120,"country":103,"countryCode":104,"cosmosGeoPoint":121,"geoPoint":125,"contacts":126},"Zhongshan Hospital, Fudan University","Shanghai","Shanghai Municipality","200032",{"type":106,"coordinates":122},[123,124],121.45806,31.22222,{"lat":124,"lon":123},[127],{"name":128,"role":93,"phone":129,"phoneExt":62,"email":130},"Jian Zhou, M.D","86-21-64041990","pumczhaohong@126.com",{"type":132,"investigatorFullName":62,"investigatorTitle":62,"investigatorAffiliation":62,"oldNameTitle":62,"oldOrganization":62},"SPONSOR","100600167",false,"NCT07093970","A Study of MRG006A in the Treatment of Patients With Advanced Solid Tumors","A Phase I\u002FII, Open-label, Multi-center, Dose Escalation and Expansion Study to Assess the Safety, Tolerability, Efficacy and Pharmacokinetics of MRG006A in Patients With Advanced Solid Tumors","Inclusion Criteria:\n\n1. Understand and provide written informed consent and comply with the requirements set forth in the protocol.\n2. age ≥ 18 years, ≤ 75 years.\n3. Expected survival ≥ 3 months.\n4. For patients with stage I and II disease, tumor tissue samples for GPC3 and P53 testing must be provided.\n5. Patients with histologically or cytologically confirmed advanced solid tumors.\n6. At least one measurable lesion according to RECISTv1.1 and mRECIST (HCC patients).\n7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n8. Organ function must meet basic requirements.\n9. Women who are pregnant or breastfeeding are not included in this study.\n10. Female and male patients of childbearing potential must agree to take adequate measures.\n\nExclusion Criteria:\n\n1. Moderate and above thoracoabdominal pelvic fluid and pericardial effusion with clinical symptoms.\n2. History of liver failure and hepatic encephalopathy.\n3. Portal vein tumor thrombus involving both the main portal vein and left and right branches, or involving both the main portal vein and mesenteric vein needs to be excluded. The tumor involves the vena cava, or has formed a vena cava tumor thrombus.\n4. Residual toxicity due to previous anti-tumor therapy or clinically significant laboratory abnormalities higher than grade 1 (CTCAEv5.0).\n5. For liver cancer, previous or current central nervous system metastases and\u002For meningeal metastases. Patients with treated stable brain metastases from non-hepatic cancers may participate.\n6. Patients at high risk of bleeding.\n7. Severe cardiac insufficiency within 6 months prior to enrollment.\n8. Pulmonary embolism or deep venous thrombosis within 3 months before the first study drug treatment;\n9. History of gastrointestinal perforation, fistula, and bowel obstruction, extensive bowel resection, Crohn 's disease, ulcerative colitis, or chronic diarrhea for the past 6 months.\n10. Patients with double cancer and multiple cancer.\n11. Uncontrolled or poorly controlled disease.\n12. History of ventricular tachycardia or torsades de pointes.\n13. Previous or combined interstitial pneumonia, severe chronic obstructive pulmonary disease with respiratory failure, severe pulmonary insufficiency, symptomatic bronchospasm and other medical history;\n14. Allergic reactions to any component or excipient of MRG006A, or known Grade ≥ 3 allergic reactions to other prior anti-GPC3 or other monoclonal antibodies.\n15. Acute or chronic active hepatitis B or C infection.\n16. Active or clinically poorly controlled serious infection.\n17. Receiving anti-tuberculosis treatment or receiving anti-tuberculosis treatment within 1 year before the first dose.\n18. People infected with human immunodeficiency virus (HIV), known syphilis infection requiring treatment.\n19. Use of systemic corticosteroids within 4 weeks prior to first treatment.\n20. Use of strong CYP3A4 inducers, strong CYP3A4 inhibitors within 14 days or 5 times the half-life prior to the first dose.","ALL","17 Years","85 Years",{"count":143,"type":144},343,"ESTIMATED","INTERVENTIONAL",[147,148],"PHASE1","PHASE2","The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG006A in patients with advanced solid tumors.",[151],"Advanced Solid Tumors",[72,153,151],"Antibody Drug Conjugate (ADC)","2026-01-20",{"date":156,"type":157},"2026-01-22","ACTUAL",{"date":159,"type":157},"2024-07-24",{"date":161,"type":144},"2028-12",{"name":5,"class":6},2]